Consolidated Financial Results for the 3rd Quarter of Fiscal 2021

from the beginning

Consolidated Financial Results for the 3rd Quarter of Fiscal 2021 and Full‐Year Forecasts

Disclaimer

Highlights

01. Consolidated Financial Results and Business Review for the 3Q of Fiscal 2021 (FY Ending March 31, 2021)

3Q of Fiscal 2021 (1)Consolidated Financial Results

Updates: January to December

3Q of Fiscal 2021 (2)Endoscopic Solutions Division(ESD)

3Q of Fiscal 2021 (3)Therapeutic Solutions Division(TSD)

3Q of Fiscal 2021 (4)Scientific Solutions Division(SSD)

Statement of Financial Position

Consolidated Cash Flows

02. Forecasts for Fiscal 2021

Fiscal 2021 Consolidated Forecasts

Fiscal 2021 Forecasts by Business Segment

03. Transforming into a Truly Global Medtech Company

Committed to Corporate Reforms

Key Product Catalysts: Endoscopic Solutions Division(As of Feb.12, 2021)

Acquired Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

Key Product Catalysts: Therapeutic Solutions Division(As of Feb. 12, 2021)

Olympus Opportunities in Respiratory

Olympus Approach to Reusable and Single-use Endoscope

@

04. Appendix

Supplementary Materials: 3Qof Fiscal2021 Factors that AffectedConsolidated Operating Profit

Supplementary Materials: 3Q of Fiscal 2021 Results by Segment

Supplementary Materials: 3Q of Fiscal 2021 Discontinued Operation(IMD)

Supplementary Materials: Expenditures etc.

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7